Post hoc analysis of the LUCENT-1 trial (928 participants with ulcerative colitis): higher baseline serum eosinophils (≥0.57×10⁹/L) were associated with more clinical response to mirikizumab induction (80% vs 65.7%; aOR 2.31), remission and endoscopic improvement.
Secondary analysisn = 928
Wong et al. Serum and Histologic Eosinophilia as a Predictive Biomarker of Response to Mirikizumab in Ulcerative Colitis